FMC Corp Dossier - Source-backed chat

FMC Corp

FMCNYSE

SectorMaterials

IndustryAgricultural Inputs

Beta (adjusted)0.59

Intrinsic Value $39.97median of 3 methodsbased on filings through 30 Jun 2026

Market Price $8.56Price as of 1 Oct 2026

Significantly undervaluedIntrinsic value is 367% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

marker beyond scale (+367%)

Data confidence Sign in to view data confidence

Market Cap $1.3B

Enterprise Value $4.8B

Shares Outstanding 125.3M diluted

Moat Rating None

Next Earnings Date4 Nov 2026

Last ex-dividend30 Sep 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

FMC Corporation is navigating a severe cyclical downturn in the crop protection market, compounded by high leverage and the patent cliff of its flagship insecticide, Rynaxypyr. While the stock has plummeted over 60% year-over-year and trades at historically low multiples, management is actively executing a $1 billion debt-reduction program through non-core asset sales (including the $252 million divestiture of its India commercial business) and driving growth in its next-generation active ingredients. A 'Hold' recommendation is warranted as the market awaits concrete signs of free cash flow stabilization and successful post-patent execution in the second half of 2026.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets14 analysts · as of 18 Aug 2026

Low · most bearish analyst$11.00

Mean target$13.52

High · most bullish analyst$21.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

Generic competition for Rynaxypyr accelerates faster than expected in Latin America and North America, severely compressing margins. Asset sales stall, leaving the company burdened with its $4.1 billion net debt load amid junk credit ratings. Free cash flow remains negative, forcing further dividend cuts or dilutive capital raises.

Base CaseCentral scenario

The agricultural downcycle stabilizes, and FMC successfully executes its $1 billion debt paydown target, reducing leverage. Branded Rynaxypyr pricing repositioning successfully defends market share against generic entrants, while new active ingredients (Isoflex, rimisoxafen) scale to meet the $300M-$400M target. EBITDA recovers toward the midpoint of the $670M-$730M guidance.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong pipeline of 19 new active ingredients in development, with four (Isoflex, fluindapyr, Dodhylex, rimisoxafen) actively scaling and targeting $300M-$400M in 2026 sales.
Aggressive restructuring and cost-saving initiatives under Project Foundation to optimize the global manufacturing footprint.
Active execution of a $1 billion debt-reduction program, highlighted by the $252 million sale of the India commercial business.

Key Investment Risks

High leverage with $4.1 billion in net debt and recent downgrades to junk status by major credit rating agencies.
Patent expiration of flagship diamide insecticide Rynaxypyr, exposing its core revenue stream to low-cost generic competition.
Prolonged agricultural downcycle, channel inventory destocking, and weak farmer sentiment limiting near-term demand recovery.

Thesis Invalidation Triggers

Failure to complete key asset divestitures, leading to a breach of leverage covenants.
A sharp acceleration in Rynaxypyr pricing erosion beyond the guided mid-single-digit declines.
New active ingredient sales significantly missing the guided $300 million floor for fiscal year 2026.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.